OSA

What is Obstructive Sleep Apnea?

Obstructive sleep apnea (OSA) affects more than 25 million Americans and hundreds of millions more around the globe.

It is characterized by repetitive partial or complete upper airway obstructions that occur during sleep, resulting in intermittent hypoxemia, loud snoring, sleep disruption, and daytime sleepiness or fatigue. OSA is associated with metabolic and cardiovascular co-morbidities and possibly increased mortality and can impair work productivity, reduce functional ability, and lower quality of life. 

CHALLENGES & OPPORTUNITIES

Managing OSA

It is important to diagnose and treat Obstructive Sleep Apnea, as it can have serious long-term health consequences.

Current treatment options are either cumbersome or uncomfortable to use yielding reduced adherence, or are unpredictable in their efficacy. In addition, most clinical metrics used today to define apnea severity have problems in their measurement and ability to predict adverse outcomes. 

  • Malhotra A, Ayappa I, Ayas N, Collop N, Kirsch D, Mcardle N, Mehra R, Pack AI, Punjabi N, White DP, Gottlieb DJ; for SRS task force. Metrics of Sleep Apnea Severity: Beyond the AHI. Sleep. 2021 Mar 9

A NEW APPROACH

Our Science

Apnimed is developing oral pharmaceutical treatments for OSA.

Apnimed’s lead product candidate, AD109, represents a novel pharmacological approach that is specifically designed to target the neurological control and activation of upper airway dilator muscles to maintain an open airway during sleep. If approved, AD109 would be the first medication indicated to address the disordered nighttime breathing that characterizes obstructive sleep apnea.